Clinical Trial Update: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating niraparib plus dostarlimab for patients with advanced cancers and active brain metastases. The study is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain Metastases | Phase 2 | Status: RECRUITING